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Abstract 
Functionalized fullerenes with specific physicochemical properties have been developed for 
cancer diagnosis and therapy. Notably, metallofullerene is a new class of magnetic resonance 
imaging (MRI) contrast-enhancing agent, and may have promising applications for clinical di-
agnosis. Polyhydroxylated and carboxyl fullerenes have been applied to photoacoustic im-
aging. Moreover, in recent years, functionalized fullerenes have shown potential in tumor 
therapies,  such  as  photodynamic  therapy,  photothermal  treatment,  radiotherapy  and 
chemotherapeutics. Their antitumor effects may be associated with the modulation of oxi-
dative stress, anti-angiogenesis, and immunostimulatory activity. While various types of novel 
nanoparticle agents have been exploited in tumor theranostics, their distribution, metabolism 
and toxicity in organisms have also been a source of concern among researchers. The present 
review summarizes the potential of fullerenes as tumor theranostics agents and their possible 
underlying mechanisms are discussed. 
Key  words:  Functionalized  fullerenes,  nanoparticles,  cancer  diagnosis,  cancer  therapy, 
theranostics. 
Introduction 
Buckminsterfullerene (C60) is a carbon allotrope 
discovered  in  1985  [1].  Since  then,  fullerenes  have 
attracted  much  attention  and  been  widely  investi-
gated. After the main problem of poor solubility was 
solved  by  chemical  or  supramolecular  approaches 
(usually a chemical modification on the surface of the 
sphere), various functionalized fullerenes were syn-
thesized to achieve promising results [2]. For exam-
ple, the empty interior cavity of the fullerene molecule 
makes it an ideal site for containment of a metal atom 
to  form  metallofullerene.  This  special  structure  of 
metallofullerene shows advantages compared to the 
metal itself or metal chelate complexes. One of their 
most important and novel electronic properties is the 
so-called  intra-fullerene  electron  transfer  from  the 
encaged metal atom(s) to the fullerene cage(s), which 
has been suggested to use in MRI [3]. Most likely due 
to its unique chemical structure, C60 possesses inter-
esting photo-physical properties and generates reac-
tive oxygen species (ROS) by exposure to visible light, 
making it a potentially strong agent for photodynamic 
therapy in biological systems [4].  
The specific physicochemical properties of full-
erenes  promoted  the  development  of  tumor 
theranostic;  consequently,  functionalized  fullerenes 
are  currently  under  extensive  investigation  due  to 
their  potential  application  to  tumor  imaging  and 
therapy (Table 1).  
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Table 1. Application of various functionalized fullerenes to tumor theranostics. 
Applications  Types of functionalized fullerenes  Predominant characteristics  Refer-
ences 
Cancer 
diagno-
sis 
Magnetic resonance 
imaging (MRI) 
Gd@C82(OH)40  higher signal enhancement at a dose of 1/20 of 
commercial Gd-DTPA 
[10]  
    Gd@C82O2(OH)16(C(PO3Et2)2)10  high affinity to bone  [11]  
    Gd@C60[C(COOH)2]10  excellent cellular uptake efficiency without any ad-
junctive agent, obtained by a non-chromatographic 
procedure with more abundant M@C60 fraction 
[13, 14]  
    Gd3N@C80[DiPEG(OH)x]  the highest relaxivity  [15, 16]  
    Gd3N@C80(OH)∼26(CH2CH2COOM)∼1
6(M=Na or H) 
readily synthesized with high yield, further qualified 
diffusion time 
[17]  
    Gd@C82O6(OH)16-(NHCH2CH2COO
H)8 
Gd3N@C80(OH)26(CH2CH2COOH)16 
conjugated to an protein/peptide for ―tumor tar-
geted‖ imaging 
[18, 19]  
  Photoacoustic 
ag-
ing(&Photothermal 
treatment) 
C60(OH)xOyNaz  ―acoustic-explosion‖ after exposure to laser irradia-
tion 
[20, 21]  
Cancer 
therapy 
Photodynamic 
therapy 
C60 conjugated with PEG,/pullulan  strong tumor suppression coupled with light irradi-
ation  
[26, 27]  
    125I–C60(OH)x  accumulated in tumors readily and persistently  [28]  
    C60-PEG-Gd   a good agreement between the time profile of the 
PDT effect and the detection of positive MRI signal 
[29]  
    (γ-CyD)2/C60  singlet oxygen -mediated phototoxicity  [31, 32]  
    C60-porphyrin  induce carcinoma cell death through either a 
1O2-mediated photoreaction process or a free radical 
mechanism  
[33]  
    N-methylpyrrolidinium-fullerene 
(BB4) 
induce apoptosis by producing Type 1 ROS  [34, 35]  
  Radiotherapy  212Pb@C60 malonic acids  stable during β--decay of 212Pb to 212Bi, attenuates the 
myelotoxicity of 212Pb 
[36]  
    177LuxLu(3-x) N@C80  conjugated to IL-13 for RIT  [37]  
  Chemotherapeutics  Gd@C82(OH)22   efficiently inhibit the growth of murine H22 hepa-
toma with low toxicity, reverse tumor resistance by 
enhancing the endocytosis of cisplatin via nanopar-
ticle-mediated penetration 
[40, 43]  
    C60(OH)x  significant tumor inhibition, anti-metastatic activity  [41, 42]  
    C60, C60(Nd)  induce autophagy-mediated chemosensitization  [44, 62]  
 
 
Functionalized fullerenes for tumor imaging  
Magnetic resonance imaging  
Among many imaging strategies, such as optical 
imaging (OI), computed tomography (CT), MRI, ul-
trasound (US), and radionuclide imaging with posi-
tron  emission  tomography  (PET)  or  single  photon 
emission  computed  tomography  (SPECT),  MRI  is  a 
versatile, non-invasive medical diagnostic technique 
that can provide both physiological and anatomical 
information, while not requiring the use of ionizing 
radiation. In addition, in many applications it is often 
the  most  sensitive  method  available  to  depict  soft 
tissues.  Therefore,  it  has  been  extensively  used  for 
brain  and  central  nervous  system  imaging,  for  as-
sessing cardiac function and for detecting abnormal 
tissues such as tumors [5, 6]. However, the difference 
between MR images of normal and abnormal tissues 
is  often  not  large  enough;  therefore,  specific  exoge-
nous contrast agents are often required to increase MR 
image quality and obtain higher resolution and sensi-
tivity.  
Paramagnetic metal ions, especially gadolinium 
(Gd3+),  have  been  proposed  as  MR  contrast  agents. 
Conventional T1 contrast agents have been developed 
in the form of more stable and less toxic metalloche-
lates, including  gadolinium(III) diethyltriaminepent-
aacetic  acid  (Gd(III)-DTPA)  and  gadolini-
um-tetraazacyclododecanetetraacetic  acid 
(Gd(III)-DOTA),  which  are  currently  marketed  as 
Omniscan®  and  ProHance®,  respectively  [6,  7]. 
However, for Gd3+ chelate complexes, the main limi-
tation is the release of metal ions in vivo during met-
abolic  processes  and  the  subsequent  toxicity.  Since Theranostics 2012, 2(3) 
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gadolinium-containing  metallofullerenes  were  first 
used as excellent contrast agents for MRI with rela-
tively  high  spatiotemporal  resolution,  they  have  at-
tracted much attention for their potential application 
in clinical diagnosis. The Gd3+ ion was encapsulated 
in the fullerene cage, which is a structure that pre-
serves  the  properties  of  the  metal  ion,  avoids  any 
leakage and thus prevents its dissociation in vivo [7]. 
After specific chemical modifications, various Gd@Cn 
(n=60,  82)  derivatives  have  been  developed  and 
widely explored (Figure 1A, B and C) [8, 9]. 
Gd@C82(OH)n has shown a water proton relax-
ivity  twenty  times  higher  than  the  commercially 
available  Gd-DTPA.  After  intravenous  (iv)  admin-
istration  of  Gd@C82(OH)40  at  a  dose  of  1/20  of  the 
typical clinical dose of Gd-DTPA, a higher signal en-
hancement was measured in vivo (Figure 2) [10]. To 
achieve  better  bio-distribution,  modification  of  the 
fullerene  cages  with  biologically  active  groups  has 
often been proposed. For example, the organic phos-
phonate modified Gd@C82O2(OH)16(C(PO3Et2)2)10 has 
exhibited high affinity to bone [11].   
 
 
Figure  1.  Depiction  of  (A)  Gd@C60[C(COOH)2]10 [8],  (B)  Gd@C60(OH)x [8],  (C)  Gd@C82(OH)22 [9],  (D)  C60(OH)x [38],  (E) 
C60[C(COOH)2]2 [39]. Adapted with permission from [8]. 
 
 
 
Figure 2. (A) T1-weighted MRI of (a)Gd@C82(OH)40 and Gd-DTPA phantom at a concentration of 0.05, 0.1, and 0.2 mmol Gd/L, (B) 
CDF1 mice before and 30 min after i.v. administration of Gd@C82(OH)40 via tail vein as a dose of 5 μmol Gd/kg [10]. Theranostics 2012, 2(3) 
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For a long time, the greatest obstacle to the prac-
tical  application  of  Gd@C82  was  its  low  production 
yield and requirement for potentially laborious HPLC 
purification. Recently, without the complicated pro-
cess of purification, Grushko et al. tested the MRI effi-
ciency  of  a  mixture  of  gadolinium  endometallofull-
erenes (with high content of more than 80 mol.%) and 
empty  fullerenes,  and  found  that  the  T1-weighted 
signal  intensity  was  15~30  times  higher  than  the 
commercial ―Gadovist‖ contrast agent [12]. 
After the Gd@C82 contrast agent was developed, 
another  type  of  gadofullerene  derivative, 
Gd@C60[C(COOH)2]10  was  also  found  to  possess  a 
higher relaxivity (4.6 mM-1 s-1 at 20 MHz and 40 °C) 
compared to that of commercial Gd3+ chelate. It was 
used as an efficient cellular magnetic resonance im-
aging label in vitro and a 2.5-fold signal enhancement 
was shown in T1-weighted MRI of labeled cells com-
pared to control cells. The cellular uptake characteris-
tics  of  this  gadofullerene  were  significant  and  non-
specific, and an excellent labeling efficiency (98-100%) 
was  achieved  without  any  adjunctive  agent,  com-
pared  to  Gd@C82(OH)40.  Furthermore, 
Gd@C60[C(COOH)2]10  was  the  first  highly  soluble, 
air-stable discrete molecule based on the more abun-
dant  M@C60  fraction  of  metallofullerenes,  obtaining 
by a non-chromatographic procedure [13, 14].  
The  Gd3N@C80  fullerene  exhibiting  the  highest 
relaxivity has seen wider use because of the presence 
of  three  Gd3+  ions  per  molecule.  Functionalized 
trimetallic nitride endohedral metallofullerene species 
Gd3N@C80 [DiPEG5000(OH)x] has been used to per-
form  high  water  hydrogen  MR  imaging  relaxivity 
(R1)  when  used  at  a  lower  concentration,  with  an 
equivalent  efficiency  compared  with  commercial 
agents.  After  it  was  directly  infused  into  a  tumor 
bearing brain, improved tumor delineation was pos-
sible  in  comparison  with  the  intravenously  injected 
conventional Gd3+ chelate [15]. Zhang et al. also com-
pared the 1H MRI relaxivities of Gd3N@C80 fullerenes 
with  PEG  of  four  different  molecular  weights 
(350-5000 Da), and found that 350/750 Da PEG de-
rivatives exhibited the highest relaxivity compared to 
longer  chain  length  ones,  5000  Da  PEG  derivatives 
[16].  At  nearly  the  same  time, 
Gd3N@C80(OH)26(CH2CH2COOM)16 (M=Na or H) was 
readily synthesized by Shu et al. with high yield. The 
longitudinal  and  transverse  relaxivities  R1  and  R2 
were  50  times  larger  than  those  of  Gd3+ 
poly(aminocarboxylate) complexes, such as commer-
cial Omniscan and Magnevist. Furthermore, the new 
derivatives were more compact, diffused more slowly 
and lingered for a longer time than commercial agents 
and  Gd3N@C80[PEG5000(OH)x]  [17].  These  results 
gave  greater  impetus  to  the  development  of 
metallofullerenes as MRI contrast agents. 
In the previously  mentioned studies,  most  im-
aging was obtained by directly administering fuller-
enes  into  tumor  tissue,  therefore  tumor-targeting  is 
certainly a subsequent challenge for tumor imaging. 
Antibodies of the green ﬂuorescent protein (anti-GFP) 
were  conjugated  to  endohedral  gadofulleride, 
Gd@C82O6(OH)16-(NHCH2CH2COOH)8,  as  a  model 
for  ―tumor-targeted‖  imaging  agents,  and  could  be 
detected  by  using  a  fluorescent  GFP  probe.  Results 
revealed that the antibody activity was well preserved 
after the conjugation, and the MRI activity was higher 
than that of unconjugated gadofulleride [18]. Recent-
ly,  a  more  encouraging  result  was  obtained.  A  car-
boxyl  functionalized  metallofullerene 
Gd3N@C80(OH)26(CH2CH2COOH)16  was  successfully 
conjugated  to  an  interleukin-13  (IL-13)  peptide,  the 
receptor  of  which  was  expressed  on  glioblastoma 
multiforme cells. This preliminary finding exhibited 
the  potential  of  functionalized  gadolinium 
metallofullerenes  for  tumor  targeting  and  imaging 
[19]. 
Photoacoustic imaging 
Recently, an attractive new therapeutic concept 
called  ‗acoustic-explosion‘  was  suggested  for  some 
functionalized  fullerenes,  polyhydroxy  fullerenes 
(PHF;  C60(OH)xOyNaz)  and  carboxy  fullerenes  (CF; 
C60(C(COOH)2)3). Concomitant with the exposure to 
low-intensity  (<  102  W  cm-2)  continuous-wave  laser 
irradiation in the presence or absence of oxygen, sus-
tained glowing of functionalized fullerenes was ob-
served. When this process was performed in cancer 
cells, a faint pop was heard following irradiation, in-
dicating  the  photoacoustic  properties  of  functional-
ized fullerenes. To investigate their potential for can-
cer  imaging,  researchers  then  used  a  mechanical 
scanning  photoacoustic  system  with  a  single  trans-
ducer to collect the acoustic signal, and embedded it 
in a phantom together with functionalized fullerenes. 
After laser irradiation in a water tank, high contrast 
photoacoustic  images  of  functionalized  fullerenes 
were obtained. Similarly, the photoacoustic imaging 
experiment  yielded  promising  results  in  tu-
mor-bearing  nude  mice.  Excellent  contrast  between 
tumor and non-tumor regions was shown after intra-
tumoral injection of PHF, and the laser energy used 
was only one-third of the maximum permissible ex-
posure level of 29.5 mJ cm−2 for a 785 nm pulsed laser 
as  established  by  the  American  National  Standards 
Institute [20, 21]. This new finding suggests potential 
applications of functionalized fullerenes for obtaining 
photoacoustic images (Figure 3).  Theranostics 2012, 2(3) 
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Figure 3. (A) Visible light emission from functionalized fullerenes irradiated with a 785-nm laser [21]. (B) Photoacoustic imaging and 2-D 
signal mapping of tumors in living mice before (Left) and after (Right) intratumoral injection of polyhydroxy fullerenes [20]. 
 
Functionalized fullerenes for tumor therapy 
Photodynamic therapy  
Photodynamic therapy (PDT) is a non-invasive 
treatment for various types of tumor. The combina-
tion of a photosensitizing agent and focused irradia-
tion is used to elicit specific, controlled production of 
reactive oxygen species in a localized area, leading to 
cell destruction through several pathways. By using 
highly focused light irradiation, photodynamic ther-
apy has the potential to act specifically at the desired 
site of action with low levels of collateral damage to 
healthy cells [22]. Fullerenes can efficiently generate 
reactive oxygen species when exposed to visible light, 
which means it may be an effective cytotoxic agent. 
The anatomical characteristics of tumor, such as hy-
perpermeable  vasculature  and  an  immature  lymph 
system, make large-sized substances accumulate and 
remain longer in tumor tissues than in normal tissues. 
After the ideal molecular size, water-solubility, and 
tumor  targeting  were  developed  through  various 
modifications,  functionalized  fullerenes  are  now 
available for cancer PDT both in tumor cells and tu-
mor-bearing mice [23-25]. Many researches have been 
carried out to demonstrate this potential application 
of functionalized fullerenes. 
When  C60  was  conjugated  with  polyethylene 
glycol (PEG), pullulan, etc., strong tumor suppression 
was shown after the conjugate was injected intrave-
nously  into  tumor-bearing  mice  coupled  with  light 
irradiation  [26,  27].  To  confirm  tumor  uptake  of 
C60(OH)x,  125I-labeled  fullerenol,  125I-C60(OH)x  were 
administered to five tumor-bearing mice. The accu-
mulation ratios of 125I-C60(OH)x in tumor compared to 
normal muscle tissue (T/N) and blood (T/B) at dif-
ferent  time  points  revealed  that  C60(OH)x  could  be 
accumulated  in  several  tumors  readily  and  persis-
tently,  especially  in  mouse  H22  hepatocarcinoma, 
suggesting that it could be used as a good photosen-
sitizer in photodynamic tumor therapy [28]. To ele-
vate the PDT effect by controlling the treatment time, 
Gd3+-chelated  C60-PEG  (C60-PEG-Gd)  was  obtained 
from  mixing  gadolinium  acetate  solution  with 
C60-PEG-DTPA, which was prepared by introducing 
diethylenetriaminepentaacetic  acid  (DTPA)  to  the 
terminal group of C60-PEG. The MRI activity was in-
troduced into the C60-PEG of PDT photosensitizers by 
the chelate incorporation of Gd3+ ions and provided a 
non-invasive way to detect the time course of C60-PEG 
accumulating  in  the  tumor  tissue.  There  was  good 
agreement between the time profile of the PDT effect 
and the detection of a positive MRI signal. These re-
sults indicated that C60 could be a potent photosensi-
tizing  agent  for  photodynamic  tumor  therapy  after 
proper modifications [29].  
Two oxidative mechanisms are considered to be 
mainly implicated in the photodamage of cells. One is 
free radicals and the other is singlet molecular oxygen 
(1O2), generated through electron transfer and energy 
transfer, respectively. These two mechanisms may be 
determined by some important factors. For example, 
C60  induced  DNA  cleavage  occurs  mainly  through 
reduced  active  oxygen  radicals  such  as  superoxide 
anion radical (O2—·) and hydroxyl radical (·OH) under 
physiological  conditions,  while  1O2  was  generated 
effectively in nonpolar solvents [30]. Besides, aggre-Theranostics 2012, 2(3) 
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gation is a well-accepted factor that could deactivate 
the  excited  electronic  states  of  photosensitizers  and 
cause further loss of photoreactivity. Zhao et al. found 
that  γ-cyclodextrin  bicapped  pristine  C60 
[(γ-CyD)2/C60]  was  in  a  monomeric  state  in  water 
whereas C60(OH)24 was aggregated. It could be used 
to explain the phototoxicity induced by (γ-CyD)2/C60 
toward human keratinocytes. The toxicity was mainly 
mediated by singlet oxygen and much higher than its 
water-soluble derivative C60(OH)24 [31, 32]. Compared 
to Type 2 photochemistry mechanism, Type 1 is more 
depend  on  the  surrounding  oxygen  concentration; 
thus,  some  functionalized  fullerenes  acting  through 
the Type 1 pathway may be relatively more effective 
in  hypoxic  tumors.  C60-porphyrin  could  induce 
HepG2 human larynx-carcinoma cell death through 
either a 1O2-mediated photoreaction process or a free 
radical  mechanism  under  anaerobic  conditions  [33]. 
N-methylpyrrolidinium-fullerene (BB4) was found to 
be a powerful photosensitizer with the ability to kill 
cancer cells in vitro and in a mouse model of dissem-
inated  peritoneal  carcinomatosis  after  illumination 
with  white light. BB4 can induce apoptosis by pro-
ducing Type 1 ROS, rather than singlet oxygen, i.e. a 
Type 2 mechanism [34, 35]. 
Photothermal treatment 
Recently, certain functionalized fullerenes, espe-
cially  polyhydroxy  fullerenes  (PHF)  and  carboxy 
fullerenes (CF) were found to be heated to their igni-
tion temperature by exposure to low-intensity (< 102 
W cm-2) continuous-wave laser irradiation, which was 
likely because of distortion of the symmetrical cage 
structure. This heating property would be extremely 
advantageous for cancer therapy, when a negatively 
charged PHF coating on silica nanoparticles function-
alized  with  positively  charged  amine  groups  was 
dosed to A549 cells and localized destruction of cells 
was induced by irradiation with a near-infrared laser 
[21].  
Moreover,  when  tumors  were  exposed  to 
near-infrared light after injected with PHF nanoparti-
cles, they decreased in cross-sectional area by an av-
erage of 32% within 2 hours of treatment, with only a 
blister visible 20 hours post-treatment. In addition, a 
concomitant  faint  audible  sound  was  heard  accom-
panied by bubble formation and bursting of 
the irradiated cells after exposure to a 785 nm 
laser. Thus, the rapid tumor shrinkage may 
be explained by both photothermal ablation 
and  ―acoustic-explosion‖  mechanisms  (Fig-
ure 4) [20].  
 
 
Figure 4. Treatment of a mice tumor with polyhydroxy 
fullerenes.  (A)  Experimental  setup  for  photothermal 
ablation of tumor with CP-0.25 (chitosan-polyhydroxy 
fullerenes)  nanoparticles.  (B)  Photographs  of  mouse 
tumor 2 hours (Left) and 20 hours (Right) after laser 
irradiation,  only  a  blister  was  visible  after  20  hours 
(within dotted lines). (C) Histological sections of re-
maining  tumor  stained  with  hematoxylin  and  eosin 
demonstrate areas of necrosis [20]. 
 
 
Therapeutic Nuclear Medicine 
While the potential of metallofullerenes 
on MRI was developed vigorously, research 
on  another  application  of  functionalized 
fullerenes  to  therapeutic  nuclear  medicine 
was also performed. Based on a similar prin-
ciple, metallic radionuclides encapsulated in 
fullerenes  can  be  protected  in  the  empty 
carbon  cage  stably,  eliminating  any  unde-
sired  toxicity  induced  by  the  leakage  and 
catabolism of administered radionuclides.  Theranostics 2012, 2(3) 
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The availability of radio-fullerenes in therapeutic 
nuclear medicine was then proven by distribution and 
stability  evaluations.  Diener  et  al.  prepared  the 
α-emitting  212Pb@C60 malonic acids for the first time 
and investigated the bio-distribution of the untarget-
ed water-soluble radio-fullerene in mice and its sta-
bility during β--decay of  212Pb to  212Bi. It was shown 
that 212Pb@C60 malonate prevented the 212Pb from ac-
cumulation in bone, attenuated the myelotoxicity of 
212Pb, and exhibited a rather slow clearance. This ra-
dio-fullerene also appeared stable in solution (about 
36% of the 212Bi released) [36]. The above results sug-
gested that water-soluble fullerenes might be suitable 
as cancer radiopharmaceuticals.  
Effective targeted delivery of radionuclides is the 
primary challenge in radio-immunotherapy (RIT). By 
conjugating the radio-fullerenes with an antibody that 
is specific for receptors expressed preferentially on the 
cancer cells, radioisotopes can be delivered to cancer 
cells. After encapsulation of the β-emitter  177Lu in a 
fullerene  cage,  an  IL-13  peptide  that  targets  an 
over-expressed  receptor  in  glioblastoma  multiforme 
tumors  was  successfully  conjugated  to  the 
177LuxLu(3-x)N@C80  [37].  However,  the  efficiency  of 
these  radio-fullerenes  for  tumor  targeting  RIT  re-
quires further investigation in the living body or tu-
mor cells. 
Chemotherapeutics  
Besides  surgery,  chemotherapeutics  is  another 
principal  method  for  tumor  therapy.  However,  the 
high  toxicity  and  easily  developed  drug  resistance 
considerably confine the chemotherapeutic effect. In 
recent  years,  functionalized  fullerenes  have  been 
found to have some good characteristics to aid with 
antitumor treatments, and some of them have exhib-
ited the potential for tumor inhibition (Figure 1C, D 
and E) [9, 38, 39]. In 2005, we found that gadolinium 
endohedral  metallofullerenol  (Gd@C82(OH)n  nano-
particles) can efficiently inhibit the growth of murine 
H22 hepatoma without obviously adverse effects on 
important organs, having nearly no direct toxic effect 
to tumor cells [40], which is an advantage over con-
ventional anti-tumor drugs. Zhu et al. [41] also tested 
the tumor-inhibitory effect of C60(OH)x on the same 
model. In the C60(OH)x-treated group, significant tu-
mor  inhibition  rates  and  reduced  damage  to  liver 
were shown, in accordance to the histological results 
of inhibited tumor infiltration. Additionally, the an-
ti-metastatic  activities  of  fullerenol  C60(OH)20  was 
observed in cancer metastasis models [42]. Moreover, 
some  fullerenes  could  increase  the  chemo- 
sensitization  of  tumor  cells  to  chemotherapeutic 
agents  and  result  in  antitumor  drug-mediated  cell 
death, especially in some drug-resistant cancer cells 
[43, 44]. Thereafter, great attention was focused on the 
underlying mechanisms of the antitumor activity of 
fullerenes as follows: 
1) Anti-angiogenesis 
Angiogenesis is one of the most important fac-
tors for the progression of tumor, by  supplying tu-
mors with oxygen and nutrients [45]. As tumors can 
generate their own blood vessels from the surround-
ing vasculature [46, 47], anti-angiogenesis treatments 
can  inhibit  growth  and  metastasis  of  various  solid 
tumors [48].  
Meng et al. investigated the anti-angiogenic ac-
tivity of Gd@C82(OH)22 and found that the nanoparti-
cle can simultaneously down-regulate more than 10 
angiogenic  factors,  which  was  confirmed  in vivo  by 
decreasing tumor  microvessel density and lowering 
the nutrient supply to tumor tissues. A similar result 
was also obtained in another anti-angiogenesis study 
of C60(OH)20 (Figure 5) [42, 49]. 
 
2) Modulation of oxidative stress 
ROS such as superoxide radical anion, hydrogen 
peroxide, singlet oxygen, and hydroxyl radical, which 
can  cause  oxidative  stress,  are  considered  to  be  an 
important  part  in  the  mechanism  of  carcinogenesis. 
ROS can induce lipid peroxidation, protein fragmen-
tation,  DNA  damage,  damage  to  tumor-suppressor 
genes and enhance the expression of proto-oncogenes. 
It  has  been  reported  that  various  carcinoma  cells 
synthesize ROS at an elevated rate in vitro, and many 
tumors  are  under  persistent  oxidative  stress  in vivo 
[42]. As water-soluble fullerenes showed high inhibi-
tory activity on many kinds of tumor growth in mice, 
and it is well established that fullerenes and their de-
rivatives  possess  a  unique  capacity  for  scavenging 
ROS [50], the relationship between the two functions 
of the nanoparticles was investigated. 
The  ROS  scavenging  capability  of 
[Gd@C82(OH)22]n was verified by electron  spin reso-
nance  (ESR)  [51],  as  well  as  in  tumor  tissues  of 
C60(OH)20 treated mice [42], which meant that the an-
titumor mechanism of fullerenes may be related to its 
capacity  to  modulate  oxidative  stress  in  tu-
mor-bearing models. On the other hand, Injac et al. 
found that fullerenol C60(OH)24 had protective effects 
on the primary organs (heart, liver, lung and kidney) 
against chronic toxicity induced by doxorubicin, and 
thus may be useful as a potential organo-protector for 
anticancer therapy [52-55]. These results may increase 
the  feasibility  of  applying  fullerenes  to  cancer 
chemotherapeutics. Theranostics 2012, 2(3) 
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3) Immunological activity  
Our  previous  studies  have  demonstrated  that 
water-soluble C60(OH)20 and Gd@C82(OH)22 nanopar-
ticles have specific immunomodulatory effects on T 
cells and macrophages, and up-regulated the immune 
response in vivo, including the polarization of the cy-
tokine balance towards Th1 (T-helper cell type 1) cy-
tokines,  which  particularly  increase  TNF-α  produc-
tion, a very important factor helping to scavenge and 
kill tumor cells [9, 38]. These results indicated effec-
tive  immunological  mechanisms  of  functionalized 
fullerenes (Figure 6). 
 
Figure 5. Mechanism by which C60(OH)20 suppresses carcinoma metastasis in vivo. (A) (A–C) Photos of lungs after soaking in Bouin’s 
solution showing spontaneous pulmonary breast cancer metastases (white arrows). (B) Administration of C60(OH)20 can decrease oxi-
dative stress, the content of angiogenic factors(TNF-α, VEGF and PDGF) and neovascularization in tumor tissues, inhibition of which 
diminish transmission of cancer cells to lung tissues [42]. 
 
Figure 6. Possible immune-associated pathways by which Gd@C82(OH)22 nanoparticles inhibit the growth of tumors. (A) In comparison 
to the untreated saline group, IFN-γ and TNF-α expression levels in mouse tumor tissues increased markedly in the group treated with 
0.5 mmol/kg/day Gd@C82(OH)22 nanoparticles. (B)The Gd@C82(OH)22 nanoparticles injected in the abdominal cavity are mostly en-
gulfed by macrophages and other phagocytes through phagocytosis, whilst a few enter the blood directly through the peritoneum or 
mesentery. The Gd@C82(OH)22 nanoparticles stimulate macrophages and T cells to release several kinds of cytokines, such as, IL-2, IL-4, 
IL-5, TNF-α and IFN-γ, which then triggers a series of signal pathways of immune responses and possibly promotes tumor cell apoptosis 
[9]. Theranostics 2012, 2(3) 
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Zhang et al. found that Gd@C82(OH)22 could ef-
fectively  activate  dendritic  cells  (DCs)  and  macro-
phages,  which  are  the  most  important  antigen  pre-
senting cells (APC), as well as up-regulate the expres-
sion of co-stimulatory molecules and MHC molecules, 
thus enhancing the APC function of DCs and macro-
phages as illustrated by their capacity to activate al-
logeneic  T  cells.  More  evidence  was  also  given  to 
demonstrate  the  immune  activity  of  Gd@C82(OH)22, 
which could increase the production of Th1 cytokines 
and  promote  macrophages  secreting 
pro-inflammatory cytokines such as IL-6 and TNF-α 
[56, 57]. 
Moreover, there are few reports about the anti-
genicity of C60 derivatives. Chen et al. found that mice 
immunized  with  the  fullerene-bovine  thyroglobulin 
conjugates  generated  a  population  of  fuller-
ene-specific antibodies of the IgG isotype, including a 
subpopulation that was cross-reacted with a C70 full-
erene [58]. The specificity of the monoclonal antibody 
for the C60 fullerene was determined by competitive 
inhibition,  and  the  anti-C60  antibodies  were  able  to 
interact with single walled carbon nanotubes, which 
was imaged using atomic force microscopy [59, 60]. 
4) Overcoming tumor resistance to chemotherapeutic 
drugs 
For  cisplatin-resistant  cancer  (CP-r)  cells, 
Gd@C82(OH)22  alone  had  no  obvious  inhibition  on 
tumor growth, although it has been indicated that the 
metallofullerene could improve the sensitivity of CP-r 
tumors to cisplatin, as an effective inhibition of CP-r 
tumors growth was observed following cisplatin plus 
nanoparticle treatment in vitro and in vivo. Transfer-
rin-labeled  experiments  have  shown  that  less  intra-
cellular transferrin is distributed in CP-r cells than in 
CP-s cells, indicating a possible defective endocytosis 
of the CP-r cells. Since nanoparticles have been used 
as drugs or gene carriers for cancer treatment, it was 
posited  that  [Gd@C82(OH)22]n  nanoparticles  reverse 
tumor resistance by enhancing the endocytosis of cis-
platin via nanoparticle-mediated penetration through 
the plasma membrane of the CP-r cells, and this hy-
pothesis  was  conﬁrmed  by  increased  cisplatin  ad-
ducts in NP and CP-treated CP-r cells measured by 
ICP-MS.  Restoring  defective  endocytosis  and  other 
related  possible  mechanisms  for  overcoming  tumor 
resistance to cisplatin by using fullerenes could lead 
to new chemotherapies for cancer [43].  
5) Autophagy-mediated chemo-sensitization 
The main therapeutic goal of cancer treatment is 
to trigger tumor-selective cell death. One of the cellu-
lar pathways receiving much attention in recent years 
is autophagy, a highly-regulated intracellular process 
for the degradation of long-lived proteins and dam-
aged organelles. Autophagy can be either a cell death 
pathway  or  a  cell  survival  pathway  depending  on 
many factors such as the degree of cell damage and 
intactness of apoptotic pathways [61]. Undoubtedly, 
promoting  autophagy-mediated  cell  apoptosis  is  of 
most concern for tumor therapy. 
Zhang  et  al.  have  performed  comprehensive 
work on the modulation of autophagy in cancer cells 
by fullerene C60 nanocrystals. They found that HeLa 
cells treated with nano-C60 exhibited autophagic fea-
tures, such as LC3 puncta formation, and many more 
autophagic vacuoles including autophagosomes and 
autolysosomes. Nano-C60 at non-cytotoxic concentra-
tions  sensitized  chemotherapeutic  killing  of  cancer 
cells in a photo-enhanced and ROS-dependent path-
way,  which  was  further  verified  via  GFP-LC3  dot 
formation that was effectively reduced by free radical 
scavengers  in  the  dark  treatments  [44].  A  much 
greater  potential  in  the  induction  of  autophagy  by 
another  C60  derivative,  C60(Nd),  was  also  reported 
[62]. All above results prompt that fullerenes might be 
available to be an efficient chemo-sensitizer in cancer 
therapy. 
Bio-distribution and Toxicity 
Although  the  diverse  potential  applications  of 
fullerene and its derivatives have been exploited in 
cancer diagnosis and therapy, it is necessary to con-
sider their biocompatibility and toxicity for organisms 
prior to their widespread utilization and production. 
Since  fullerene  derivatives  with  different  modifica-
tions have distinct biological behaviors, understand-
ing these will help in the safe development of fuller-
ene-based drugs [63, 64]. 
Bio-distribution and excretion 
The  dynamic  distribution  of  fullerenes  within 
the body is influenced by several factors, including 
the  particle  size,  various  modifications,  and  admin-
istration pathways. Studying these factors can help to 
identify potential target tissues of fullerene and assess 
the toxicity at particular target sites.  
Unlike oral administration, whereby 14C-labeled 
C60 is not efficiently absorbed and excreted primarily 
in  the  feces,  C60  injected  intravenously  was  cleared 
from  the  blood  circulation  rapidly,  accumulated 
mainly within the liver and remained there for a long 
time,  and  then  was  cleared  slowly  from  the  liver 
(nearly all was eliminated 13 days after injection). All 
these results suggest that the liver is a potential target 
for fullerene accumulation and toxicity contributes to 
the metabolism of C60 (C60 metabolites were identified Theranostics 2012, 2(3) 
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within the liver) and facilitates the removal of fuller-
enes from the body within the feces [65-67]. By com-
parison, the water-soluble C60 had a wider tissue dis-
tribution, which might be attributed to its more hy-
drophilic  water-soluble  character.  99mTc-C60(OH)x  in-
jected into mice through tail veins was quickly dis-
tributed to all organs except for tissues with limited 
blood ﬂow, such as muscle. It remained throughout 
the 48 h of the study, particularly in the kidneys, bone, 
spleen and liver, and displayed a slow clearance rate 
except  for  bone,  which  showed  slightly  increasing 
accumulation within 24 h [68]. This phenomenon was 
further demonstrated by studying the distribution of 
125I-C60(OH)x,  which  was  rapidly  distributed  to  all 
organs (mainly in the kidneys, liver, bone, spleen and 
stomach) through the blood circulation and especially 
exhibited  a  rapid  and  high  uptake  in  kidneys,  fol-
lowed  by  a  fast  excretion  into  urine.  Likewise, 
125I-C60(OH)x was not found in the brain, suggesting it 
could  not  penetrate  the  blood-brain  barrier  (BBB), 
which was different from the C60 modified with di-
polar trimethylenemethane [28].  
Similarly,  Cagle  et  al.  [69]  found  that 
166Ho@C82(OH)y  was  distributed  throughout  the  en-
tire body, except for the brain and fat tissues, as early 
as 1 h after the tail-vein injection, which was different 
from  the  finding  with  metal  chelate 
(Na2[166Ho(DTPA)(H2O)]). Only the concentrations of 
166Ho in liver and bone increased from 1 to 4 h, espe-
cially in bone, which subsequently displayed a slight 
increase in concentration over 48 h (Figure 7A). These 
results were consistent with the observations for the 
bio-distribution of [Gd@C82(OH)22]n particles. Unlike 
GdCl3, [Gd@C82(OH)22]n was delivered to almost all 
observed  tissues,  but  accumulated  mostly  in  bone, 
suggesting  that  the  fullerene  cage  could  not  be  de-
stroyed in organisms and that the internal Gd3+ was 
well protected in the cage. The concentration of Gd in 
the brain was close to the baseline, suggesting that the 
[Gd@C82(OH)22]n  nanoparticles  could  not  pass 
through the BBB either (Figure 7B) [70]. The similar 
results  for  the  bio-distributions  of  C60(OH)x  and 
C82(OH)y showed that the biological properties would 
not be expected to change by incorporation of a metal 
atom within a fullerene cage. Thus, distribution and 
biocompatibility of fullerenes were usually assessed 
through ip and iv injections, and chemical modifica-
tion to the fullerene cages may play an important role 
in determining their distribution and biocompatibil-
ity.  
 
 
Figure 7. (A) Biodistribution of 166Hox@C82(OH)y in BALB/c mice at 1, 4, 24, and 48 h after injection. The animals were sacrificed, and 
organs were sampled at 1, 4, 24, and 48 h, followed by measurement of the  166Ho 80.5 KeV -emission [69]. (B) Biodistribution of 
[Gd@C82(OH)22]n nanoparticles in tumor-bearing mice (expressed as concentrations of gadolinium element, ng Gd/g wet weight) [70]. 
 
Toxicity evaluation 
To understand the toxicity of C60,  it is usually 
necessary to investigate the lethality, gross or micro-
scopic lesions, histopathological change, etc. Howev-
er, other biological responses, such as stimulation of 
the  immune  system,  regulation  of  oxidative  stress, 
and changes on the molecular level induced by full-
erenes, should generally be considered as well.  
Following  the  inhalation  pathway,  C60  and  its 
derivates  can  be  partly  deposited  in  the  lungs  and 
internalized  by  alveolar  macrophages;  a  pulmonary 
inflammatory response was elicited for a high expo-
sure dose of fullerenols (10 mg/kg) and fullerenols at Theranostics 2012, 2(3) 
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low  concentrations  (1  mg/kg)  exhibited  an  an-
ti-inflammatory property. Although slight changes in 
gene  expression  level  were  observed,  no  obviously 
toxicity  was  reported  [71,  72].  Only  when  wa-
ter-soluble polyalkylsulfonated C60 was administrated 
at extremely high dose (LD50=600 mg/kg) in an acute 
toxicity study or at a moderately high dose (up to 60 
mg/kg)  via  ip  injection,  observable  pathological  or 
lethal toxicity was induced. However, in subsequent 
study of oral exposure, fullerenes were considered to 
be nontoxic at a dose of 50 mg/kg, which was close to 
that  of  ip  administration  [73].  Even  when  the  dose 
was increased to 2,000 mg/kg, fullerite (a mixture of 
C60 and C70) has not shown to cause any acute toxicity. 
The  possible  reason  is  that  fullerenes  are  not  effec-
tively  absorbed  through  the  alimentary  tract  [74]. 
Toxicity assessment of fullerenes should therefore be 
considered comprehensively, including the exposure 
routes and the delivered dose, etc. 
After fullerenes enter into the body, they may be 
internalized  by  different  types  of  cells,  and  induce 
various  changes  inside  the  cells,  such  as  viability, 
proliferation, inflammation responses, and oxidative 
responses.  Therefore,  the  cytotoxicity  assessment  of 
fullerenes has been one of the most important aspects 
to consider when assessing the toxicity of fullerenes 
[75]. Many related studies have been performed on 
various  cell  lines.  C60  and  quaternary  ammonium 
derivatized C60 inhibited keratinocytes proliferation at 
a concentration of 2 μM and over a period of 8 days, 
which  is  relatively  long  [66].  In  both  human  skin 
(HDF)  and  liver  carcinoma  (HepG2)  cells,  wa-
ter-soluble  fullerene  species  are  less  cytotoxic  than 
pristine C60, while C60(OH)24 showed no cytotoxicity 
up to its limits of solubility, suggesting the functional 
groups  on  the  surface  of  a  fullerene  molecule  can 
dramatically  decrease  the  toxicity.  However, 
C60(OH)24 was found to induce cytotoxic morpholog-
ical  changes  within  the  HUVEC  cell  line  in  a 
dose-dependent  way,  and  only  maximal  doses  of 
fullerenes caused cytotoxic injury and/or death and 
inhibited  cell  growth  [76].  In  nearly  every  fuller-
ene-related  anti-tumor  study,  fullerenes  were  not 
found to have a direct influence on tumor cell viability 
[9, 38, 40, 42]. The diverse toxicity results of fullerenes 
reveal that the sensitivity of various tissues or cells to 
the  nanoparticles  can  be  different.  Therefore,  thor-
ough  toxicity  evaluation  of  fullerenes  before  their 
clinical application is necessary. 
Perspectives 
Due  to  their  attractive  physical,  chemical,  and 
biological  properties  and  the  availability  of  various 
methods for surface modification, fullerenes and their 
derivatives  have  been  studied  for  their  numerous 
biomedical applications, not only in tumor diagnosis 
and therapy, but also as an anti-HIV agent [77, 78], 
antimicrobial  photosensitizer  [79,  80],  antioxidants 
[52, 81, 82], and gene vector [83-85]. Some properties 
involved in these applications might create new in-
sights into fullerenes as anti-tumor therapeutics, for 
example, in gene therapy. However, since the under-
lying mechanisms related to their apparent activities 
are  not  yet  clear,  further  research  towards  a  better 
understanding is urgently needed to investigate the 
biocompatibility  and  safe  application  of  functional-
ized  fullerenes  as  diagnostic  tools  and  therapeutic 
agents.  
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